[Form 4/A] BIOXYTRAN, INC Amended Insider Trading Activity

Rhea-AI Filing Summary

Bioxytran, Inc. insider Ola Soderquist, who serves as CFO and is a 10% owner, reported multiple equity transactions dated 10/25/2024. He acquired 10,069,396 shares of preferred stock at $0.545 per share, bringing his beneficial ownership in that class to 13,976,456 preferred shares. He also acquired an additional 100,000 preferred shares at $0.005 per share, after which he held 13,876,456 preferred shares. In addition, he acquired 500,000 shares of common stock at $0.001 per share and held 500,000 common shares directly after the transaction. The filing states that some shares were issued as payment for the sale of NDPD Pharma to Bioxytran and that there was a 1:5 exchange of preferred stock into common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Soderquist Ola

(Last) (First) (Middle)

47 HAMMOND STREET

UNIT 2

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOXYTRAN, INC [ BIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
10/25/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)
10/25/2014

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
preferred	10/25/2024		J(1)		10,069,396	A	$0.545	13,976,456	D
preferred	10/25/2024		J(2)		100,000	A	$0.005	13,876,456	D
common	10/25/2024		J(2)		500,000	A	$0.001	500,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Shares were issued as payment for the sale of NDPD Pharma to Bioxytran

2. A 1:5 exchange of Preferred Stock (earlier issued under section 16b-3) into shares of Common Stock.

	Ola Soderquist	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Bioxytran (BIXT) CFO Ola Soderquist report in this Form 4/A?

He reported acquiring preferred and common shares of Bioxytran on 10/25/2024, including a large block of preferred stock and a smaller amount of common stock through issuance and exchange transactions.

How many Bioxytran preferred shares did the CFO acquire and own after the transactions?

He acquired 10,069,396 preferred shares at $0.545 and 100,000 preferred shares at $0.005. Following these transactions, he beneficially owned 13,876,456 preferred shares.

How many Bioxytran common shares did the CFO acquire in this filing?

He acquired 500,000 shares of common stock at a price of $0.001 per share and held 500,000 common shares directly after the reported transaction.

What was the consideration for some of the Bioxytran (BIXT) shares issued to the CFO?

The filing states that certain shares were issued as payment for the sale of NDPD Pharma to Bioxytran, indicating they were received as part of a business sale transaction.

What does the 1:5 exchange mentioned in the Bioxytran Form 4/A mean?

The explanation notes a 1:5 exchange of preferred stock into common stock, meaning previously issued preferred shares were exchanged for common shares at a one-for-five ratio.

What is Ola Soderquist’s role and relationship to Bioxytran (BIXT)?

He is reported as a 10% owner and an officer of Bioxytran, serving in the role of CFO, and files as a single reporting person on this Form 4/A.